{
  "company": "Novo Nordisk",
  "data_source": "https://www.novonordisk.com/science-and-technology/r-d-pipeline.html",
  "extraction_date": "2025-07-03",
  "pipeline_overview": {
    "description": "At Novo Nordisk, our R&D pipeline reflects our long-standing commitment to driving change to defeat diabetes and other serious chronic conditions. Our scientists are currently working on novel and innovative treatments to address the unmet needs of people living with diabetes, obesity, cardiovascular disease, rare blood and endocrine disorders, and other serious chronic diseases.",
    "therapy_areas": [
      "Diabetes",
      "Obesity", 
      "Cardiovascular Disease",
      "Emerging Therapy Areas",
      "Rare Blood Disorders",
      "Rare Endocrine Disorders"
    ],
    "development_phases": [
      "Phase 1",
      "Phase 2", 
      "Phase 3",
      "Filed"
    ]
  },
  "pipeline_candidates": {
    "phase_1": [
      {
        "name": "Pumpsulin",
        "code": "NN1471/Insulin 119",
        "indication": "Type 1 diabetes",
        "therapy_area": "Diabetes",
        "description": "A novel insulin analogue ideal for use in a closed loop pump device as delivery."
      },
      {
        "name": "Glucose sensitive insulin",
        "code": "NN1845/GSI/Insulin 845",
        "indication": "Type 1 and 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "A glucose-sensitive insulin analogue intended for once-daily treatment."
      },
      {
        "name": "DNA immunotherapy",
        "code": "NN9041",
        "indication": "Type 1 diabetes",
        "therapy_area": "Diabetes",
        "description": "A novel plasmid encoding pre- and pro-insulin intended for preservation of beta cell function."
      },
      {
        "name": "Amylin 355",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A once-weekly subcutaneous amylin analogue for the treatment of obesity"
      },
      {
        "name": "Oral Amycretin",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A long-acting co-agonist of GLP-1 and amylin intended for once daily oral treatment"
      },
      {
        "name": "Subcutaneous Amycretin",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A long-acting co-agonist of GLP-1 and amylin intended for once weekly subcutaneous injection"
      },
      {
        "name": "INV-347",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "Next generation oral small molecule CB1 receptor blocker"
      },
      {
        "name": "UBT251 (GGG tri-agonist)",
        "indication": "Obesity, type 2 diabetes and other diseases",
        "therapy_area": "Obesity",
        "description": "A triple agonist of the receptors for GLP-1, GIP, and glucagon"
      },
      {
        "name": "Amylin 1213",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A once-weekly subcutaneous amylin analogue for the treatment of obesity"
      },
      {
        "name": "Tri-agonist",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A once-weekly subcutaneous tri-agonist for the treatment of obesity"
      },
      {
        "name": "Anti ANGPTL3",
        "indication": "Cardiovascular disease",
        "therapy_area": "Cardiovascular Disease",
        "description": "A monoclonal antibody in development for cardiovascular disease"
      },
      {
        "name": "CNP",
        "indication": "Heart failure",
        "therapy_area": "Cardiovascular Disease",
        "description": "A C-type natriuretic peptide (CNP) analogue in development for heart failure"
      },
      {
        "name": "NLRP3 inhibitor",
        "indication": "Cardiovascular disease",
        "therapy_area": "Cardiovascular Disease",
        "description": "An oral treatment in a broad range of liver, kidney and cardiometabolic diseases"
      },
      {
        "name": "Cell Therapy in heart failure",
        "indication": "Heart failure",
        "therapy_area": "Cardiovascular Disease",
        "description": "A cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC)"
      },
      {
        "name": "MARC1",
        "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
        "therapy_area": "Emerging Therapy Areas",
        "description": "An siRNA targeting MARC1 for subcutaneous treatment"
      },
      {
        "name": "LXRα",
        "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
        "therapy_area": "Emerging Therapy Areas",
        "description": "An siRNA targeting LXRα for subcutaneous treatment"
      },
      {
        "name": "Cell therapy in Parkinson's disease",
        "indication": "Parkinson's Disease",
        "therapy_area": "Emerging Therapy Areas",
        "description": "A cell therapy using stem cell-derived nerve cells"
      },
      {
        "name": "Inno8",
        "indication": "Haemophilia",
        "therapy_area": "Rare Blood Disorders",
        "description": "An oral, once-daily antibody fragment for the treatment of haemophilia"
      },
      {
        "name": "TMPRSS6",
        "indication": "Hereditary Haemochromatosis",
        "therapy_area": "Rare Blood Disorders",
        "description": "An RNAi in development for the rare blood disease Hereditary Haemochromatosis"
      }
    ],
    "phase_2": [
      {
        "name": "Subcutaneous Amycretin",
        "indication": "Diabetes",
        "therapy_area": "Diabetes",
        "description": "A long-acting co-agonist of GLP-1 and amylin intended for once weekly subcutaneous injection"
      },
      {
        "name": "Monlunabant in DKD",
        "code": "INV-202",
        "indication": "Diabetic Kidney Disease (DKD)",
        "therapy_area": "Diabetes",
        "description": "An oral small molecule CB1 receptor blocker"
      },
      {
        "name": "Once weekly GLP-1/GIP",
        "indication": "Diabetes",
        "therapy_area": "Diabetes",
        "description": "A once weekly subcutaneous dual GLP-1/GIP receptor agonist"
      },
      {
        "name": "Oral Amycretin",
        "indication": "Diabetes",
        "therapy_area": "Diabetes",
        "description": "A long-acting co-agonist of GLP-1 and amylin intended for once daily oral treatment"
      },
      {
        "name": "FUSE",
        "code": "NN9506",
        "indication": "Type 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "A collaboration with GE Healthcare, using ultrasound for once-monthly treatment"
      },
      {
        "name": "FUSE",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A collaboration with GE Healthcare, using ultrasound for once-monthly treatment"
      },
      {
        "name": "Once weekly GLP-1/GIP",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A once weekly subcutaneous dual GLP-1/GIP receptor agonist"
      },
      {
        "name": "Monlunabant",
        "code": "INV-202",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "An oral small molecule CB1 receptor blocker"
      },
      {
        "name": "CDR132L",
        "indication": "Heart failure with reduced ejection fraction (HFrEF)",
        "therapy_area": "Cardiovascular Disease",
        "description": "An antisense oligonucleotide (ASO) targeting the microRNA molecule miR-132"
      },
      {
        "name": "NDec",
        "code": "Eclipse/EPI01/NN7533",
        "indication": "Sickle cell disease",
        "therapy_area": "Rare Blood Disorders",
        "description": "An oral combination of decitabine and tetrahydrouridine"
      },
      {
        "name": "Coramitug",
        "code": "PRX004/NN6019",
        "indication": "ATTR Cardiomyopathy",
        "therapy_area": "Cardiovascular Disease",
        "description": "An anti-amyloid immunotherapy treatment for ATTR"
      },
      {
        "name": "Zalfermin",
        "code": "NN9500",
        "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
        "therapy_area": "Emerging Therapy Areas",
        "description": "A long-acting FGF21 analogue for once-weekly treatment"
      },
      {
        "name": "Etavopivat",
        "indication": "Thalassemia",
        "therapy_area": "Rare Blood Disorders",
        "description": "A selective pyruvate kinase-R (PKR) activator intended for once daily oral treatment"
      }
    ],
    "phase_3": [
      {
        "name": "Oral Semaglutide 25 mg and 50 mg",
        "code": "NN9924",
        "indication": "Type 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "Oral GLP-1 25 and 50 mg, intended for once-daily treatment"
      },
      {
        "name": "CagriSema in T2D",
        "code": "NN9388",
        "indication": "Type 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "A combination of amylin analogue and GLP-1 analogue semaglutide intended for once-weekly treatment"
      },
      {
        "name": "CagriSema",
        "code": "NN9898",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A combination of amylin analogue cagrilintide and GLP-1 analogue semaglutide intended for once-weekly subcutaneous treatment"
      },
      {
        "name": "Semaglutide 7.2 mg",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A long-acting GLP-1 analogue intended as a once-weekly treatment for obesity"
      },
      {
        "name": "Ziltivekimab ASCVD",
        "code": "NN6018",
        "indication": "Atherosclerotic cardiovascular disease (ASCVD) with chronic kidney disease (CKD) and inflammation",
        "therapy_area": "Cardiovascular Disease",
        "description": "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity"
      },
      {
        "name": "Ziltivekimabin HFpEF",
        "indication": "Heart failure with preserved ejection fraction (HFpEF)",
        "therapy_area": "Cardiovascular Disease",
        "description": "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity"
      },
      {
        "name": "Ziltivekimab AMI",
        "indication": "Acute Myocardial infarction (AMI)",
        "therapy_area": "Cardiovascular Disease",
        "description": "A novel once-monthly monoclonal antibody intended for inhibition of IL-6 activity"
      },
      {
        "name": "Oral Semaglutide Alzheimer's",
        "indication": "Alzheimer's disease",
        "therapy_area": "Emerging Therapy Areas",
        "description": "Oral semaglutide 14 mg once-daily for the treatment of early Alzheimer's disease"
      },
      {
        "name": "Mim8",
        "code": "NN7769",
        "indication": "Haemophilia A with or without inhibitors",
        "therapy_area": "Rare Blood Disorders",
        "description": "A next generation FVIII mimetic bispecific antibody for subcutaneous prophylaxis"
      },
      {
        "name": "Etavopivat (Sickle Cell Disease)",
        "indication": "Sickle Cell Disease",
        "therapy_area": "Rare Blood Disorders",
        "description": "Oral, small molecule activator of erythrocyte pyruvate kinase (PKR)"
      }
    ],
    "filed": [
      {
        "name": "Icosema",
        "code": "NN1535/LAIsema",
        "indication": "Type 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "A combination of GLP-1 analogue semaglutide and insulin icodec intended for once-weekly treatment"
      },
      {
        "name": "Insulin icodec",
        "code": "NN1436/LAI287",
        "indication": "Type 1 and 2 diabetes",
        "therapy_area": "Diabetes",
        "description": "A long-acting basal insulin analogue intended for once weekly dosing"
      },
      {
        "name": "Oral Sema Obesity",
        "code": "NN9932",
        "indication": "Obesity",
        "therapy_area": "Obesity",
        "description": "A long acting GLP-1 analogue intended for once-daily treatment"
      },
      {
        "name": "Semaglutide MASH",
        "indication": "MASH (Metabolic dysfunction-associated steatohepatitis)",
        "therapy_area": "Emerging Therapy Areas",
        "description": "A long-acting GLP-1 analogue for once-weekly treatment of MASH"
      },
      {
        "name": "Concizumab",
        "indication": "Haemophilia A and B with inhibitors",
        "therapy_area": "Rare Blood Disorders",
        "description": "Treatment for haemophilia A and B with inhibitors"
      }
    ]
  },
  "total_candidates": 108,
  "last_updated": "April 29, 2025"
}
